profile page

Overview

Company Overview

GT Biopharma has developed a platform technology that engages the CD16 Fc receptor on NK cells, mediating tumor specific antigen targeting and an IL-15 moiety between them to induce NK cell proliferation and activation. Lead clinical programs are highlighted below. This platform technology can be applied to any known or proprietary tumor (or other target [e.g. HIV reservoirs]). Several are in research development or planned. The platform is based on the finding that the 2^nd generation TriKE® are 10-40 times more potent than 1^st generation TriKE and all TriKE development is now focused on this platform.

Pipeline

TriKE^® Clinical Pipeline

GT Biopharma’s development timeline matters because it shows where each program currently stands and what steps are planned next—information investors routinely use to evaluate a company’s progress, risk profile, and strategic focus. The advancement of GTB-3650, which has now entered a Phase 1 trial with the first patient dosed on January 21, 2025, reflects movement from preclinical research into early human testing. The pipeline graphic also indicates that several other programs—B7H3, HER2, CD19, and HIV—are in preclinical or IND-enabling stages, which helps investors understand the company’s workload, diversification, and planned development trajectory.

From an investor’s perspective, timelines like this are important because they outline upcoming scientific and regulatory events that could influence how the market evaluates a company over time. Early-stage biotech companies often experience changes in liquidity, analyst coverage, or institutional interest as programs progress from preclinical stages toward clinical trials. The concentration of multiple programs moving toward key regulatory steps may signal an active R&D cycle, giving investors clearer visibility into how the company is allocating resources and what operational priorities look like. This helps investors determine whether the company’s pipeline strategy aligns with their personal risk tolerance and investment objectives—without implying that any specific outcome or financial return will occur.